Skip to main
BAX

Baxter (BAX) Stock Forecast & Price Target

Baxter (BAX) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 0%
Buy 22%
Hold 67%
Sell 11%
Strong Sell 0%

Bulls say

Baxter International's Healthcare Systems & Technologies segment has demonstrated consistent sales growth, with increases of approximately 6% and 2% year-over-year in the first and second quarters of 2025, respectively, and projected growth of about 4% and 2% in the subsequent quarters. The company's strategic acquisition of Hillrom in late 2021 has enhanced its portfolio, enabling it to offer a broader array of medical equipment, which may further drive sales as the healthcare market adapts to evolving demands. Additionally, targeted pricing initiatives are expected to contribute positively to sales growth by approximately 100 basis points for both 2024 and 2025, bolstering Baxter's financial outlook.

Bears say

Baxter International's stock outlook is negatively impacted by a disappointing performance in the second quarter of 2025, with sales, margins, and earnings per share all falling below consensus expectations. This underperformance follows a period from 2021 to 2023 marked by operational missteps and inconsistent quarterly results, which have led to negative guidance revisions. Additionally, the company's gross margins of 40.7% and operating margins of 15.1% have both missed consensus estimates, primarily due to sales softness, manufacturing inefficiencies, and an unfavorable product mix.

Baxter (BAX) has been analyzed by 9 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 22% recommend Buy, 67% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Baxter and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Baxter (BAX) Forecast

Analysts have given Baxter (BAX) a Hold based on their latest research and market trends.

According to 9 analysts, Baxter (BAX) has a Hold consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Baxter (BAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.